Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System
Abstract Direct oral anticoagulants (DOACs) have low risk of intracranial hemorrhage compared to warfarin. We sought to clarify the different mechanisms responsible for suppression of bleeding events using the Total Thrombus-formation Analysis System (T-TAS), a flow-microchip chamber with thrombogen...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a051c3d32ddf4095a83804444ee2443f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a051c3d32ddf4095a83804444ee2443f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a051c3d32ddf4095a83804444ee2443f2021-12-02T15:06:27ZDirect Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System10.1038/s41598-017-07939-62045-2322https://doaj.org/article/a051c3d32ddf4095a83804444ee2443f2017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-07939-6https://doaj.org/toc/2045-2322Abstract Direct oral anticoagulants (DOACs) have low risk of intracranial hemorrhage compared to warfarin. We sought to clarify the different mechanisms responsible for suppression of bleeding events using the Total Thrombus-formation Analysis System (T-TAS), a flow-microchip chamber with thrombogenic surfaces. Blood samples were obtained at Off- and On-anticoagulant (trough) from 120 consecutive patients with atrial fibrillation (warfarin; n = 29, dabigatran; n = 19, rivaroxaban; n = 47, apixaban; n = 25), which were used for T-TAS to compute the area under the curve (AUC) (AR10-AUC30) in the AR chip, and to measure plasma concentrations of DOACs at On-anticoagulant. In addition, the two-dimensional area covered by thrombi (%) in the capillary was analyzed every 3 minutes after sample applications. The AR10-AUC30 correlated weakly and negatively with plasma concentrations of DOACs, and the levels at On-anticoagulant were lower in all groups than at Off-anticoagulant. AR10-AUC30 levels at Off- and On-anticoagulant were identical among the groups. The thrombi areas in early phase were significantly larger in rivaroxaban and apixaban than warfarin and dabigatran groups. The findings suggested that visual analysis of the AR-chip can identify the differential inhibitory patterns of warfarin and DOACs on thrombus formation under flow condition.Masanobu IshiiKoichi KaikitaMiwa ItoDaisuke SuetaYuichiro ArimaSeiji TakashioYasuhiro IzumiyaEiichiro YamamotoMegumi YamamuroSunao KojimaSeiji HokimotoHiroshige YamabeHisao OgawaKenichi TsujitaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Masanobu Ishii Koichi Kaikita Miwa Ito Daisuke Sueta Yuichiro Arima Seiji Takashio Yasuhiro Izumiya Eiichiro Yamamoto Megumi Yamamuro Sunao Kojima Seiji Hokimoto Hiroshige Yamabe Hisao Ogawa Kenichi Tsujita Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System |
| description |
Abstract Direct oral anticoagulants (DOACs) have low risk of intracranial hemorrhage compared to warfarin. We sought to clarify the different mechanisms responsible for suppression of bleeding events using the Total Thrombus-formation Analysis System (T-TAS), a flow-microchip chamber with thrombogenic surfaces. Blood samples were obtained at Off- and On-anticoagulant (trough) from 120 consecutive patients with atrial fibrillation (warfarin; n = 29, dabigatran; n = 19, rivaroxaban; n = 47, apixaban; n = 25), which were used for T-TAS to compute the area under the curve (AUC) (AR10-AUC30) in the AR chip, and to measure plasma concentrations of DOACs at On-anticoagulant. In addition, the two-dimensional area covered by thrombi (%) in the capillary was analyzed every 3 minutes after sample applications. The AR10-AUC30 correlated weakly and negatively with plasma concentrations of DOACs, and the levels at On-anticoagulant were lower in all groups than at Off-anticoagulant. AR10-AUC30 levels at Off- and On-anticoagulant were identical among the groups. The thrombi areas in early phase were significantly larger in rivaroxaban and apixaban than warfarin and dabigatran groups. The findings suggested that visual analysis of the AR-chip can identify the differential inhibitory patterns of warfarin and DOACs on thrombus formation under flow condition. |
| format |
article |
| author |
Masanobu Ishii Koichi Kaikita Miwa Ito Daisuke Sueta Yuichiro Arima Seiji Takashio Yasuhiro Izumiya Eiichiro Yamamoto Megumi Yamamuro Sunao Kojima Seiji Hokimoto Hiroshige Yamabe Hisao Ogawa Kenichi Tsujita |
| author_facet |
Masanobu Ishii Koichi Kaikita Miwa Ito Daisuke Sueta Yuichiro Arima Seiji Takashio Yasuhiro Izumiya Eiichiro Yamamoto Megumi Yamamuro Sunao Kojima Seiji Hokimoto Hiroshige Yamabe Hisao Ogawa Kenichi Tsujita |
| author_sort |
Masanobu Ishii |
| title |
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System |
| title_short |
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System |
| title_full |
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System |
| title_fullStr |
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System |
| title_full_unstemmed |
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System |
| title_sort |
direct oral anticoagulants form thrombus different from warfarin in a microchip flow chamber system |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/a051c3d32ddf4095a83804444ee2443f |
| work_keys_str_mv |
AT masanobuishii directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT koichikaikita directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT miwaito directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT daisukesueta directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT yuichiroarima directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT seijitakashio directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT yasuhiroizumiya directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT eiichiroyamamoto directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT megumiyamamuro directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT sunaokojima directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT seijihokimoto directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT hiroshigeyamabe directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT hisaoogawa directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem AT kenichitsujita directoralanticoagulantsformthrombusdifferentfromwarfarininamicrochipflowchambersystem |
| _version_ |
1718388467931545600 |